Interaction between paliperidone extended release and TS-1^®, an oral anticancer drug containing a 5-fluorouracil derivative, in a schizophrenic patient

Norio Yasui-FurukoriDepartment of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, JapanCorrespondence[email protected]

Kojiro HashimotoDepartment of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan

Kazutoshi KuboDepartment of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan

Tetsu TomitaDepartment of Neuropsychiatry, Graduate School of Medicine, Hirosaki University, Hirosaki, Japan

References

YangLPPloskerGLPaliperidone extended releaseCNS Drugs2007215417425 discussion 426–42717447829
PubMed Web of Science ®Google Scholar
VermeirMNaessensIRemmerieBAbsorption, metabolism, and excretion of paliperidone, a new monoaminergic antagonist, in humansDrug Metab Dispos200836476977918227146
PubMed Web of Science ®Google Scholar
ShirasakaTDevelopment history and concept of an oral anticancer agent S-1 (TS-1): its clinical usefulness and future vistasJpn J Clin Oncol200939121519052037
PubMed Web of Science ®Google Scholar
HanstenPDHornJRThe Top 100 Drug Interactions: A Guide to Patient Management2013 editionEdmonds, WAH & H Publications2013
Google Scholar
CletonATalluriKLeempoelsJNo pharmacokinetic interaction between trimethorpim and paliperidone in healthy subjects [abstract]Clin Pharmacol Ther20067922
Web of Science ®Google Scholar
ParkJYKimKAInhibitory effect of 5-fluorouracil on human cytochrome P(450) isoforms in human liver microsomesEur J Clin Pharmacol2003595–640740912904931
PubMed Web of Science ®Google Scholar